Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data

PD-L1 is a ligand that upon binding to its receptor (PD-1) on T-cells leads to T-cell anergy/and or apoptosis [1,2]. We have shown that PD-L1 is expressed in breast cancer where its expression correlates with estrogen receptor (ER) negativity [3]. To understand the mechanism of the constitutive expression of PD-L1 in tumor cells of ER negative cells we used gene-in and out approach, large scale...

متن کامل

Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.

Since their approval by regulatory agencies worldwide, the anti-PD-1 monoclonal antibodies (mAbs), as monotherapy or in combination with ipilimumab, have become the standard frontline therapy for advanced BRAF-wild-type melanoma and an eminent rival to targeted therapy in the first-line setting for unresectable BRAF-mutated melanoma. Mature survival data from randomized phase 3 trials have emer...

متن کامل

From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.

Cancer immunotherapy has made an extraordinary journey from bench to bedside. Blocking the interactions between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has emerged as a promising immunotherapy for treating cancer. Here, we review the development of drugs targeting the PD-1/PD-L1 pathway. We discuss the monoclonal antibodies (mAbs) approved or in clinical trials, peptides a...

متن کامل

Monoclonal antibodies targeting CD20

We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of mAbs. 1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20 + hema-tological malignancies, 2,3 and also has been studied in a large number of autoimmune ...

متن کامل

Monoclonal Antibodies

SUMMARY Monoclonal Antibodies are identical antibodies and Can be generated in ultimated amounts by countinuos cultures of single antibody- secreting cells. These cell lines are produced by cell fusion of normal lymphocytes to cells of a myeloma tumor cell line, which confers on the antibody producing hybrid cell, immortality and the ability grow as atumor in animals. monoclonal antibodies c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Critical Reviews in Oncology/Hematology

سال: 2020

ISSN: 1040-8428

DOI: 10.1016/j.critrevonc.2020.102891